Active Clinical Trials

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

By April 24, 2017No Comments


Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma

Estimated Enrollment: 116

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment

Study ID Numbers: NCI-2011-02015|S0905|CDR0000665415|U10CA180888|U10CA032102

Study First Received: February 5, 2010

Last Updated: April 5, 2017

Estimated Primary Completion Date: June 2017


Primary Outcome Measures:

Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I)|Progression-free survival (Phase II)|Overall survival (Phase II)|Response (Phase II)|Toxicity assessed using NCI CTCAE version 4.0 (Phase II)

Sponsors and Collaborators:

National Cancer Institute (NCI)

Website Link:

Leave a Reply

Call Now ButtonCall Now